Hummingbird Bioscience Analysis

Develop ADCs for hard-to-treat cancers; Engineer monoclonal antibodies for autoimmune diseases; Design precision therapies with deep and durable clinical responses; Conduct global clinical trials for oncology and autoimmune indications; Provide Phase II-ready therapeutics to partners like Percheron Therapeutics

Hummingbird Bioscience primarily focuses on engineering biotherapeutics, particularly antibody-based therapeutics, targeting precision medicine for cancer and autoimmune diseases.

Hummingbird Bioscience primarily focuses on engineering biotherapeutics, particularly antibody-based therapeutics, targeting precision medicine for cancer and autoimmune diseases.

Hummingbird Bioscience has developed several key innovations and products in the biotech sector, particularly focusing on monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). Notable products include:

1. HMBD-001: A monoclonal antibody targeting HER3, currently in clinical trials for squamous cell carcinoma and metastatic castration-resistant prostate cancer (mCRPC).
2. HMBD-002: An anti-VISTA monoclonal antibody in clinical trials for multiple solid tumors, aimed at enhancing anti-tumor immune responses.
3. HMBD-009: A bispecific antibody targeting BCMA-TACI, under evaluation for multiple myeloma.
4. HMBD-501: An ADC targeting HER3, licensed to Endeavor BioMedicines for treating multiple solid tumors.
5. HMBD-802: A novel dual-payload ADC targeting HER2, presented at the EORTC-NCI-AACR symposium.
6. Partnerships: Collaborations with companies like Merck and Endeavor BioMedicines to advance their antibody therapies.

These innovations reflect Hummingbird Bioscience's commitment to advancing precision medicine and improving treatment outcomes for patients with challenging diseases.

Hummingbird Bioscience was involved in a recent funding round through its licensing of technology to Callio Therapeutics, which secured $187 million in a Series A financing round that closed on March 3, 2023. This funding is aimed at advancing multi-payload antibody-drug conjugate technology.

Hummingbird Bioscience has received regulatory approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for a first-in-human phase 1 trial of its product HMBD-001, which is aimed at treating advanced cancers.

Hummingbird Bioscience has received several awards and recognitions in the biotech field, including:

1. The Most Promising Innovation title at Singapore's SG:D Techblazer Awards 2020, which is the nation's highest accolade for tech innovation.
2. The BioSpectrum Asia Startup of the Year Award 2022, with Special Jury Recognition.

Hummingbird Bioscience has established several significant partnerships and collaborations in the biotech industry, including:

1. Synaffix: A $150 million licensing agreement to develop a next-generation antibody-drug conjugate (ADC).

   • Source

2. Novogene: A strategic partnership aimed at expanding precision medicine testing for individuals with NRG1-fusion driven cancers in China, enhancing biomarker-driven patient enrollment in clinical trials of Hummingbird's lead program, HMBD-001.

   • Source

3. EDDC (Experimental Drug Development Centre): A three-year partnership to co-develop novel antibodies for cancer treatment.

   • Source

4. Tempus: Collaboration to harness AI-driven precision medicine to accelerate the clinical development of HMBD-001 in HER3 driven cancers.

   • Source

5. Merck: A collaboration to evaluate HMBD-001 in squamous non-small cell lung carcinoma, with Merck supplying cetuximab for the study.

   • Source

6. Amgen: A partnership to co-discover novel therapeutics using Hummingbird's rational antibody discovery platform.

   • Source

Licensed HMBD-002 to Percheron Therapeutics (Phase II-ready); Appointed Dipti Thakkar, PhD as COO in May 2025; Pipeline includes ADCs and monoclonal antibodies with clinical proof-of-concept readouts; Focus on targets with strong biological and clinical validation; HQ in Singapore with US presence in Houston, Texas

Hummingbird Bioscience has received several awards and recognitions in the biotech field, including:

1. The Most Promising Innovation title at Singapore's SG:D Techblazer Awards 2020, which is the nation's highest accolade for tech innovation.
2. The BioSpectrum Asia Startup of the Year Award 2022, with Special Jury Recognition.

Hummingbird Bioscience has established several significant partnerships and collaborations in the biotech industry, including:

1. Synaffix: A $150 million licensing agreement to develop a next-generation antibody-drug conjugate (ADC).

   • Source

2. Novogene: A strategic partnership aimed at expanding precision medicine testing for individuals with NRG1-fusion driven cancers in China, enhancing biomarker-driven patient enrollment in clinical trials of Hummingbird's lead program, HMBD-001.

   • Source

3. EDDC (Experimental Drug Development Centre): A three-year partnership to co-develop novel antibodies for cancer treatment.

   • Source

4. Tempus: Collaboration to harness AI-driven precision medicine to accelerate the clinical development of HMBD-001 in HER3 driven cancers.

   • Source

5. Merck: A collaboration to evaluate HMBD-001 in squamous non-small cell lung carcinoma, with Merck supplying cetuximab for the study.

   • Source

6. Amgen: A partnership to co-discover novel therapeutics using Hummingbird's rational antibody discovery platform.

   • Source